PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze DCF forecasts for the company and compare them with competitors.
81.00K
Worse than SGMO's revenue of 176.23M.
-92.14%
Worse than SGMO's revenue growth rate of 58.34%.
-51.13M
Better than SGMO's ebitda of -87.43M.
-63123.46%
Worse than SGMO's ebitda margin of -49.61%.
-51.92M
Better than SGMO's ebit of -109.62M.
-64098.77%
Worse than SGMO's ebit margin of -62.20%.
790.00K
Better than SGMO's depreciation of 22.19M.
76.68M
Worse than SGMO's total cash of 81.00M.
94662.96%
Better than SGMO's cash as percentage of revenue of 45.96%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
7.95M
Better than SGMO's accounts payable of 15.26M.
9818.52%
Worse than SGMO's payables as percentage of revenue of 8.66%.
-153.00K
Worse than SGMO's capital expenditure of -21.16M.
-188.89%
Better than SGMO's capex as percentage of revenue of -12.00%.
4.99%
Better than SGMO's weighted average cost of capital (wacc) of 9.13%.
5.02%
Better than SGMO's cost of equity of 9.58%.
4.08%
Better than SGMO's cost of debt of 4.40%.
-0.23
Better than SGMO's beta of 1.10.
30.07M
Better than SGMO's diluted shares outstanding of 174.44M.
1.57M
Better than SGMO's total debt of 38.10M.
49.31M
Worse than SGMO's total equity of 409.94M.
50.89M
Worse than SGMO's total capital of 448.05M.
3.09%
Better than SGMO's debt weighting of 8.50%.
96.91%
Better than SGMO's equity weighting of 91.50%.
-51.92M
Better than SGMO's ebiat of -107.50M.
-53.46M
Better than SGMO's unlevered free cash flow of -110.48M.
2.00%
Equal to SGMO's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than SGMO's net debt of -7.10M.
71.33M
Better than SGMO's equity value of -4.28B.
2.37
Better than SGMO's equity value per share of -24.52.
Analyze analyst forecasts for the company and compare them with competitors.
42.82M
Worse than SGMO's estimated revenue of 300.07M.
-8.56M
Better than SGMO's estimated ebitda of -269.14M.
-0.59
Worse than SGMO's estimated eps of 0.26.
-17.89M
Worse than SGMO's estimated net income of 45.65M.
-8.56M
Better than SGMO's estimated ebit of -277.39M.
1.59B
Worse than SGMO's estimated sg&a expense of 159.11M.